File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Inhaled RNA Therapy: From Promise to Reality

TitleInhaled RNA Therapy: From Promise to Reality
Authors
Keywordsaerosol
mRNA
nonviral vector
pulmonary delivery
respiratory diseases
Issue Date2020
PublisherElsevier Ltd, Trends Journals. The Journal's web site is located at http://www.elsevier.com/locate/tips
Citation
Trends in Pharmacological Sciences, 2020, v. 41 n. 10, p. 715-729 How to Cite?
AbstractRNA-based medicine is receiving growing attention for its diverse roles and potential therapeutic capacity. The largest obstacle in its clinical translation remains identifying a safe and effective delivery system. Studies investigating RNA therapeutics in pulmonary diseases have rapidly expanded and drug administration by inhalation allows the direct delivery of RNA therapeutics to the target site of action while minimizing systemic exposure. In this review, we highlight recent developments in pulmonary RNA delivery systems with the use of nonviral vectors. We also discuss the major knowledge gaps that require thorough investigation and provide insights that will help advance this exciting field towards the bedside.
Persistent Identifierhttp://hdl.handle.net/10722/287700
ISSN
2023 Impact Factor: 13.9
2023 SCImago Journal Rankings: 3.232
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChow, MYT-
dc.contributor.authorQIU, Y-
dc.contributor.authorLam, JKW-
dc.date.accessioned2020-10-05T12:01:58Z-
dc.date.available2020-10-05T12:01:58Z-
dc.date.issued2020-
dc.identifier.citationTrends in Pharmacological Sciences, 2020, v. 41 n. 10, p. 715-729-
dc.identifier.issn0165-6147-
dc.identifier.urihttp://hdl.handle.net/10722/287700-
dc.description.abstractRNA-based medicine is receiving growing attention for its diverse roles and potential therapeutic capacity. The largest obstacle in its clinical translation remains identifying a safe and effective delivery system. Studies investigating RNA therapeutics in pulmonary diseases have rapidly expanded and drug administration by inhalation allows the direct delivery of RNA therapeutics to the target site of action while minimizing systemic exposure. In this review, we highlight recent developments in pulmonary RNA delivery systems with the use of nonviral vectors. We also discuss the major knowledge gaps that require thorough investigation and provide insights that will help advance this exciting field towards the bedside.-
dc.languageeng-
dc.publisherElsevier Ltd, Trends Journals. The Journal's web site is located at http://www.elsevier.com/locate/tips-
dc.relation.ispartofTrends in Pharmacological Sciences-
dc.subjectaerosol-
dc.subjectmRNA-
dc.subjectnonviral vector-
dc.subjectpulmonary delivery-
dc.subjectrespiratory diseases-
dc.titleInhaled RNA Therapy: From Promise to Reality-
dc.typeArticle-
dc.identifier.emailChow, MYT: mytchow@hku.hk-
dc.identifier.emailLam, JKW: jkwlam@hku.hk-
dc.identifier.authorityLam, JKW=rp01346-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1016/j.tips.2020.08.002-
dc.identifier.pmid32893004-
dc.identifier.pmcidPMC7471058-
dc.identifier.scopuseid_2-s2.0-85090489942-
dc.identifier.hkuros314832-
dc.identifier.volume41-
dc.identifier.issue10-
dc.identifier.spage715-
dc.identifier.epage729-
dc.identifier.isiWOS:000572690600007-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0165-6147-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats